ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 638

The Progression of Brain MRI Biomarker of Cognitive Impairment (White Matter Hyperintensity) in Systemic Lupus: A Clinical and Imaging Longitudinal Study

Jamal Mikdashi1 and Umran Ashruf2, 1Division of Rheumatology and Clinical Immunology, University of Maryland School of Medicine, Baltimore, MD, 2Radiology and Diagnostic Imaging, University of Maryland School of Medicine, Baltimore, MD

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Neuroimaging and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus: Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose: SLE patients are at high risk for accumulation of white matter hyperintensity (WMH) on brain MRI which has been correlated with cognitive impairment. Our goal is to determine whether the progression of WMH in newly diagnosed SLE patients predicts increased risk of cognitive impairment.

Methods: Brain MR T2 weighted images were compared at baseline and annually for 5 years among newly diagnosed SLE patients, presenting with neuropsychiatric SLE (NPSLE), {(n= 30), [ mean age 37.6 years, 73 % African American, and 90 % women]},  and age- and gender- matched non NPSLE patients (n= 25), and  healthy controls (n=20) to assess WMH burden (mild, moderate or severe). Standard cognitive tests were examined at enrollment and at end of study. Demographic and clinical manifestations were compared among the groups. Significant variables in the analyses, depression, cardiovascular risk factors and worsening of WMH grade using dichotomous measures were entered into multivariable and Cox proportional hazard analyses to determine their contribution to cognitive impairment.

Results: At baseline, 59 MRI were normal and16 had WMH lesions (NPSLE = 9, non NPSLE= 4 and controls = 3). The WMH burden was higher among NPSLE patients compared to non NPSLE patients (OR= 3.1, 95 % CI: 0.7- 13.2, p value =0.09). At baseline, frontal and parieto -occipital lesions were more frequent among NPSLE patients, whereas periventricular lesions were more frequent among non NPSLE patients or controls. At end of study, 24 patients had normal MRI findings and 21 had new and increased WMH lesions (NPSLE =13, non NPSLE =6, control= 2). The rate of WMH burden progression was variable across the groups. NP SLE patients had a faster rate of accumulation of WMH lesions, as compared to non NPSLE (OR =3.5, 95 % CI: 1.1-10.7; p value= 0.03). The median number of impaired cognitive domains increased, regardless of the presence of baseline WMH lesions particularly among NPSLE compared to non NPSLE or controls.

Ischemic strokes and MRI -defined incident infarcts (OR = 5.8; 95% CI = 1.2–29.4; p value = 0.04), and worsened WMH grade (OR = 4.3; 95% CI = 2.1–16.3; p value = 0.03), were associated with increased risk of cognitive impairment in the areas of attention, processing speed and executive function.  Hydroxychloroquine use was associated with reduced risk for WMH progression (OR= 0.3, 95 % CI: 0.1- 0.7; p value= 0.02), but not cognitive impairment.

Conclusion: The progression of WMH has prognostic relevance for long-term cognitive outcome in newly diagnosed SLE. Strategic preventive measures are needed to optimally target individuals at highest risk of cognitive decline.


Disclosure:

J. Mikdashi,
None;

U. Ashruf,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-progression-of-brain-mri-biomarker-of-cognitive-impairment-white-matter-hyperintensity-in-systemic-lupus-a-clinical-and-imaging-longitudinal-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology